Thursday, May 02, 2024
Optomed USA has launched the Optomed Aurora AEYE, a handheld AI fundus camera designed to detect diabetic retinopathy of more than mild severity instantly. This device allows diabetic patients to undergo immediate eye screenings in primary care settings, facilitating early detection and intervention before referral to an eye care specialist.
The Optomed Aurora AEYE is the only FDA-cleared handheld AI fundus camera available. Clinical trials have shown diagnostic sensitivity ranging from 92% to 93% and specificity from 89% to 94%, ensuring reliable results for over 99% of patients. Its non-mydriatic operation and single-image per eye approach ensure swift and precise screening.
This technology empowers primary care providers to swiftly detect diabetic retinopathy on-the-spot, with results available in just 60 seconds. By eliminating guesswork, it streamlines the referral process: red signals referral to an eye care specialist, while green indicates a re-screening in 12 months.
Engineered with a high-contrast optical design and a 50-degree field-of-view, it excels in detecting subtle retinal changes at an early stage. Additionally, its autofocus and auto-exposure functions enhance user-friendliness, while its capability to capture digital images facilitates seamless communication with eye care providers.
With approximately 50% of diabetic Americans neglecting their annual eye exams, the Optomed Aurora AEYE addresses a critical gap in diabetic retinopathy screening. Offering autonomous screening in primary care settings not only enhances clinic adherence to quality measures but also qualifies for reimbursement. Most importantly, it plays a pivotal role in averting vision loss and blindness among diabetics at risk.
Source: prnewswire.com
